MALVERN, Pa., Nov. 02, 2016 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the third quarter ended September 30, 2016.
Company Highlights
- Recognized highest quarterly revenue in Company’s history of $53.1 million, a 22% increase over the prior year
- Recorded $4.1 million GAAP net income for the third quarter
- Realized highest quarterly adjusted EBITDA in Company’s history of $12.2 million, a 40% increase over the prior year
- Experienced 9% year over year growth in patient volume
- Generated $26.4 million of cash from operations year to date, the highest in the Company’s history
- Repaid $11.5 million of revolving debt in early October
- Received positive coverage decision from Anthem for use of MCT for certain patients
President and CEO Commentary
Joseph H. Capper, President and Chief Executive Officer of BioTelemetry, Inc., commented: “With our strong third quarter results, we delivered our seventeenth consecutive quarter of year over year revenue growth and our seventh consecutive quarter of year over year net income growth. Our commitment to our core operating principles continues to deliver outstanding results, as evidenced by our 40% adjusted EBITDA growth. Our top line momentum, with 22% growth, was driven by the success of our sales strategy to be the single source provider of cardiac monitoring solutions. As a result, we continue to grow substantially faster than the market, posting 9% patient volume growth, highlighted by double digit MCT growth. Additionally, our second quarter acquisitions had a positive impact on both our top and bottom lines.
“BioTelemetry is on track to deliver record results for 2016, and we expect to achieve the higher end of our adjusted EBITDA guidance of $44 to $46 million. Looking forward to 2017, we expect the Company’s growth to continue to outpace the cardiac monitoring industry. This will be driven, in part, by the expansion of our unmatched product portfolio with the upcoming launch of our next generation device, the MCOTTM Patch, and by maximizing the opportunity to now service certain Anthem patients with MCT. We are also uniquely positioned to capitalize on other opportunities to use our technology to improve patient care and lower costs. With our proven strategy and strong performance, we are confident that our growth will continue into 2017.”
Third Quarter Financial Results
Revenue for the third quarter 2016 was $53.1 million compared to $43.5 million for the third quarter 2015, reflecting an increase of $9.6 million, or 22.0%. Healthcare revenue increased $4.7 million due to increased patient volumes and higher patient pricing due to a favorable product mix as well as higher MCT Medicare pricing. Research revenue increased $4.9 million, due to the acquisition of VirtualScopics during the second quarter.
Gross profit for the third quarter 2016 increased to $32.9 million, or 61.9% of revenue, compared to $26.3 million, or 60.6% of revenue, for the third quarter 2015. The increase in gross margin percentage was due to Healthcare volume efficiencies, higher Healthcare pricing as well as reduced costs related to shipping and device communications. These increases were partially offset by the impact of our acquisitions, which caused a shift in our revenue mix toward Research which carries a lower margin than our Healthcare business.
On a GAAP basis, operating expense for the third quarter 2016 was $27.9 million, compared to $23.3 million for the second quarter 2015. On an adjusted basis1, operating expense for the third quarter 2016 was $25.5 million compared to $21.9 million for the third quarter 2015. The adjusted operating expense excludes $2.4 million of other charges for the third quarter 2016 primarily related to patent litigation and the integration of the second quarter acquisitions and $1.4 million for the third quarter 2015 primarily related to patent litigation. The increase in adjusted expense was driven by the addition of $2.0 million related to our acquired companies, a $1.0 million increase in employee related expense, a $0.3 million increase in bad debt expense and $0.3 million of additional consulting expense primarily related to ongoing product development.
Interest and other loss, net was $0.6 million for the third quarter 2016 compared to $0.4 million for the third quarter 2015. The increase was primarily due to higher interest expense stemming from borrowings under the revolving credit facility.
On a GAAP basis, net income for the third quarter 2016 was $4.1 million, or $0.14 per diluted share, compared to net income of $2.5 million, or $0.08 per diluted share, for the third quarter 2015. Excluding the $2.4 million of other charges1, adjusted net income for the third quarter 2016 was $6.5 million, or $0.21 per diluted share. This compares to adjusted net income of $3.9 million, or $0.13 per diluted share, for the third quarter 2015, which excludes the impact of $1.4 million of other charges.
Liquidity
As of September 30, 2016, total cash was $32.3 million, an increase of $6.8 million compared to June 30, 2016. During the quarter ended September 30, 2016, the Company generated $8.9 million of cash from operations. In addition, the Company used $2.8 million of cash during the quarter for capital expenditures, primarily medical devices. Consolidated days sales outstanding decreased to 48 days as of September 30, 2016, down from 49 days as of June 30, 2016.
As of September 30, 2016, the Company had total indebtedness of $37.4 million. On October 11, 2016, the Company repaid $11.5 million of the outstanding borrowings under the revolving credit facility.
______________________________________
1 The Company believes that its adjusted financial results, which exclude Other charges, offer a meaningful representation of the Company’s performance as they exclude expenses that are not necessary to support the Company’s ongoing business.
Conference Call
BioTelemetry, Inc. will host an earnings conference call on Wednesday, November 2, 2016 at 5:00 PM Eastern Time. The call will be simultaneously webcast on the investor information page of our website, www.gobio.com. The call will be archived on our website for two weeks.
About BioTelemetry
BioTelemetry, Inc., formerly known as CardioNet, Inc., is the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care. The Company currently provides cardiac monitoring services, original equipment manufacturing with a primary focus on cardiac monitoring devices and centralized cardiac core laboratory services. More information can be found at www.gobio.com.
Cautionary Statement Regarding Forward-Looking Statements
This document includes certain forward-looking statements within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “expect,” “anticipate,” “estimate,” “intend,” “plan,” “believe,” “promises” and other words and terms of similar meaning. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including important factors that could delay, divert, or change any of these expectations, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, our ability to successfully integrate acquisitions into our business and the effect such acquisitions will have on our results of operation, effectiveness of our cost savings initiatives, relationships with our government and commercial payors, changes to insurance coverage and reimbursement levels for our products, the success of our sales and marketing initiatives, our ability to attract and retain talented executive management and sales personnel, our ability to identify acquisition candidates, acquire them on attractive terms and integrate their operations into our business, the commercialization of new products, market factors, internal research and development initiatives, partnered research and development initiatives, competitive product development, changes in governmental regulations and legislation, the continued consolidation of payors, acceptance of our new products and services, patent protection, adverse regulatory action, and litigation success. For further details and a discussion of these and other risks and uncertainties, please see our public filings with the Securities and Exchange Commission, including our latest periodic reports on Form 10-K and 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
| Three Months Ended | ||||||||||||
| Consolidated Statements of Operations | (unaudited) | |||||||||||
| (In Thousands, Except Per Share Amounts) | ||||||||||||
| September 30, 2016 | September 30, 2015 | |||||||||||
| Revenues | $ | 53,055 | $ | 43,492 | ||||||||
| Cost of revenues | 20,189 | 17,155 | ||||||||||
| Gross profit | 32,866 | 26,337 | ||||||||||
| Gross profit % | 61.9 | % | 60.6 | % | ||||||||
| Operating expenses: | ||||||||||||
| General and administrative | 13,853 | 11,497 | ||||||||||
| Sales and marketing | 7,018 | 6,632 | ||||||||||
| Bad debt expense | 2,495 | 2,245 | ||||||||||
| Research and development | 2,137 | 1,565 | ||||||||||
| Other charges | 2,397 | 1,392 | ||||||||||
| Total operating expenses | 27,900 | 23,331 | ||||||||||
| Income from operations | 4,966 | 3,006 | ||||||||||
| Interest and other loss, net | (630 | ) | (391 | ) | ||||||||
| Income before income taxes | 4,336 | 2,615 | ||||||||||
| Provision for income taxes | (235 | ) | (137 | ) | ||||||||
| Net Income | $ | 4,101 | $ | 2,478 | ||||||||
Net income per share: | ||||||||||||
| Basic | $ | 0.15 | $ | 0.09 | ||||||||
| Diluted | $ | 0.14 | $ | 0.08 | ||||||||
| Weighted average number of common shares outstanding: | ||||||||||||
| Basic | 28,102 | 27,181 | ||||||||||
| Diluted | 30,334 | 29,311 | ||||||||||
| Nine Months Ended | ||||||||||||
| Consolidated Statements of Operations | (unaudited) | |||||||||||
| (In Thousands, Except Per Share Amounts) | ||||||||||||
| September 30, 2016 | September 30, 2015 | |||||||||||
| Revenues | $ | 154,375 | $ | 131,739 | ||||||||
| Cost of revenues | 57,961 | 53,446 | ||||||||||
| Gross profit | 96,414 | 78,293 | ||||||||||
| Gross profit % | 62.5 | % | 59.4 | % | ||||||||
| Operating expenses: | ||||||||||||
| General and administrative | 40,577 | 35,100 | ||||||||||
| Sales and marketing | 21,687 | 20,741 | ||||||||||
| Bad debt expense | 7,797 | 6,769 | ||||||||||
| Research and development | 5,888 | 5,161 | ||||||||||
| Other charges | 5,844 | 4,462 | ||||||||||
| Total operating expenses | 81,793 | 72,233 | ||||||||||
| Income from operations | 14,621 | 6,060 | ||||||||||
| Interest and other loss, net | (1,686 | ) | (1,220 | ) | ||||||||
| Income before income taxes | 12,935 | 4,840 | ||||||||||
| Provision for income taxes | (529 | ) | (260 | ) | ||||||||
| Net Income | $ | 12,406 | $ | 4,580 | ||||||||
| Net income per share: | ||||||||||||
| Basic | $ | 0.45 | $ | 0.17 | ||||||||
| Diluted | $ | 0.42 | $ | 0.16 | ||||||||
| Weighted average number of common shares outstanding: | ||||||||||||
| Basic | 27,811 | 27,063 | ||||||||||
| Diluted | 29,857 | 29,019 | ||||||||||
| Summary Financial Data | |||||||||||
| (In Thousands, except days sales outstanding) | |||||||||||
| September 30, 2016 | December 31, 2015 | ||||||||||
| (unaudited) | (unaudited) | ||||||||||
| Cash and cash equivalents | $ | 32,255 | $ | 18,986 | |||||||
| Healthcare accounts receivable, net | 15,654 | 15,179 | |||||||||
| Other accounts receivable, net | 12,794 | 8,997 | |||||||||
| Days sales outstanding | 48 | 47 | |||||||||
| Working capital | 25,657 | 23,157 | |||||||||
| Total assets | 165,211 | 124,143 | |||||||||
| Total indebtedness | 37,414 | 23,582 | |||||||||
| Total shareholders’ equity | 95,032 | 75,926 | |||||||||
Reconciliation of Non-GAAP Financial Measures
(In Thousands, Except Per Share Amounts)
In accordance with Regulation G of the Securities and Exchange Commission, the table set forth below reconciles certain financial measures used in this press release that were not calculated in accordance with generally accepted accounting principles, or GAAP, with the most directly comparable financial measure calculated in accordance with GAAP. The Company believes that its adjusted financial results, which exclude Other charges, offer a meaningful representation of the Company’s performance as they exclude expenses that are not necessary to support the Company’s ongoing business.
| Three Months Ended (unaudited) | |||||||||
| September 30, 2016 | September 30, 2015 | ||||||||
| Income from operations – GAAP | $ | 4,966 | $ | 3,006 | |||||
| Other charges (a) | 2,397 | 1,392 | |||||||
| Adjusted income from operations | $ | 7,363 | $ | 4,398 | |||||
| Net income – GAAP | $ | 4,101 | $ | 2,478 | |||||
| Other charges (a) | 2,397 | 1,392 | |||||||
| Adjusted net income | $ | 6,498 | $ | 3,870 | |||||
| Net income per diluted share – GAAP | $ | 0.14 | $ | 0.08 | |||||
| Other charges per diluted share (a) | 0.07 | 0.05 | |||||||
| Adjusted net income per diluted share | $ | 0.21 | $ | 0.13 | |||||
| Three Months Ended | |||||||||
| (unaudited) | |||||||||
| September 30, 2016 | September 30, 2015 | ||||||||
| Cash provided by operating activities | $ | 8,879 | $ | 4,164 | |||||
| Capital expenditures | (2,815 | ) | (3,641 | ) | |||||
| Free cash flow | $ | 6,064 | $ | 523 | |||||
| Three Months Ended | |||||||
| (unaudited) | |||||||
| September 30, 2016 | September 30, 2015 | ||||||
| Net income – GAAP | $ | 4,101 | $ | 2,478 | |||
| Provision for income taxes | 235 | 137 | |||||
| Interest, other loss (net) | 630 | 391 | |||||
| Other charges (a) | 2,397 | 1,392 | |||||
| Depreciation and amortization expense | 3,689 | 3,165 | |||||
| Stock compensation expense | 1,138 | 1,139 | |||||
| Adjusted EBITDA | $ | 12,190 | $ | 8,702 | |||
(a) In the third quarter 2016, the Company incurred $2.4 million of other charges primarily due to patent litigation and the acquisitions completed in the second quarter. In the third quarter 2015, the Company incurred $1.4 million of other charges primarily related to patent litigation.
Reconciliation of Non-GAAP Financial Measures
(In Thousands, Except Per Share Amounts)
In accordance with Regulation G of the Securities and Exchange Commission, the table set forth below reconciles certain financial measures used in this press release that were not calculated in accordance with generally accepted accounting principles, or GAAP, with the most directly comparable financial measure calculated in accordance with GAAP. The Company believes that its adjusted financial results, which exclude Other charges, offer a meaningful representation of the Company’s performance as they exclude expenses that are not necessary to support the Company’s ongoing business.
| Nine Months Ended (unaudited) | |||||||
| September 30, 2016 | September 30, 2015 | ||||||
| Income from operations – GAAP | $ | 14,621 | $ | 6,060 | |||
| Other charges (a) | 5,844 | 4,462 | |||||
| Adjusted income from operations | $ | 20,465 | $ | 10,522 | |||
| Net income – GAAP | $ | 12,406 | $ | 4,580 | |||
| Other charges (a) | 5,844 | 4,462 | |||||
| Adjusted net income | $ | 18,250 | $ | 9,042 | |||
| Net income per diluted share – GAAP | $ | 0.42 | $ | 0.16 | |||
| Other charges per diluted share (a) | 0.19 | 0.15 | |||||
| Adjusted net income per diluted share | $ | 0.61 | $ | 0.31 | |||
| Nine Months Ended | |||||||
| (unaudited) | |||||||
| September 30, 2016 | September 30, 2015 | ||||||
| Cash provided by operating activities | $ | 26,405 | $ | 7,153 | |||
| Capital expenditures | (8,507 | ) | (10,310 | ) | |||
| Free cash flow | $ | 17,898 | $ | (3,157 | ) | ||
| Nine Months Ended | |||||||
| (unaudited) | |||||||
| September 30, 2016 | September 30, 2015 | ||||||
| Net income – GAAP | $ | 12,406 | $ | 4,580 | |||
| Provision for income taxes | 529 | 260 | |||||
| Interest, other loss (net) | 1,686 | 1,220 | |||||
| Other charges (a) | 5,844 | 4,462 | |||||
| Depreciation and amortization expense | 10,619 | 9,124 | |||||
| Stock compensation expense | 3,757 | 3,321 | |||||
| Adjusted EBITDA | $ | 34,841 | $ | 22,967 | |||
(a) In the first three quarters of 2016, the Company incurred $5.8 million other charges primarily due to patent litigation and the acquisitions completed in the second quarter. In the first three quarters of 2015, the Company incurred $4.5 million of other charges primarily due to patent litigation as well as costs related to the integration of the 2014 acquisitions.